Haemonetics Revises Annual Guidance
(RTTNews) - Haemonetics Corporation (HAE), a healthcare company, on Thursday revised its fiscal 2026 outlook.
For the full year, the company now expects adjusted income of $4.90 to $5 per share, compared with the prior guidance of $4.80 to $5 per share.
Haemonetics now anticipates its annual revenue to decline 1% to 3%, compared with the earlier expectation for a decline of 1% to 4%.
For fiscal 2025, the company had posted adjusted income of $4.57 per share, with revenue of $1.361 billion.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.